DP
PCVX icon

Diadema Partners’s Vaxcyte PCVX Stock Holding History

Diadema Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,600
Closed -$1.95M – 121
2025
Q1 		$1.95M Buy
+51,600
New +$4.13M 0.51% 45

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diadema Partners's PCVX Position: Q1 2026 in Review

Diadema Partners increased its Vaxcyte (PCVX) stake by 9.1% in Q1 2026, buying an estimated $114K and bringing the position to 25,071 shares worth $1.46M. The position accounts for 0.25% of the portfolio, ranked #75.

Diadema Partners first reported a position in PCVX in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.86M in Q3 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Diadema Partners held 25,071 shares of Vaxcyte worth $1.46M as of Q1 2026.
  • Diadema Partners bought 2,099 Vaxcyte shares in Q1 2026, an estimated $114K.
  • Vaxcyte made up 0.25% of Diadema Partners's portfolio in Q1 2026, its #75 holding.
  • Diadema Partners first reported a position in Vaxcyte in Q4 2024 and has held it in 6 quarters since.
  • Diadema Partners's Vaxcyte position peaked at $7.86M in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.